<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel>
    <title>BORA Collection: Section for Anaesthesiology and Intensive Care (Department of Surgical Sciences)</title>
    <link>http://hdl.handle.net/1956/957</link>
    <description />
    <items>
      <rdf:Seq>
        <rdf:li resource="http://hdl.handle.net/1956/1935" />
      </rdf:Seq>
    </items>
  </channel>
  <textInput>
    <title>The Collection's search engine</title>
    <description>Search the Channel</description>
    <name>search</name>
    <link>http://bora.uib.no/simple-search</link>
  </textInput>
  <item rdf:about="http://hdl.handle.net/1956/1935">
    <title>Evidence and methodology in clinical pain trials with special focus on ketamine</title>
    <link>http://hdl.handle.net/1956/1935</link>
    <description>Title: Evidence and methodology in clinical pain trials with special focus on ketamine
&lt;br/&gt;
&lt;br/&gt;Authors: Bell, Rae Frances
&lt;br/&gt;
&lt;br/&gt;Abstract: Aims:&#xD;
To establish the evidence base for the use of the NMDA receptor antagonist ketamine in the&#xD;
treatment of acute postoperative pain and cancer pain, and in doing so, to assess the&#xD;
methodology used in acute pain and cancer pain trials.&#xD;
Methods:&#xD;
In paper I a clinical model was developed and tested. Paper II is a quantitative and&#xD;
qualitative Cochrane systematic review on perioperative ketamine for acute postoperative&#xD;
pain. Paper III is a qualitative Cochrane systematic review on ketamine as adjuvant to opioid&#xD;
for cancer pain. Paper IV is a qualitative systematic review of the methodology used in&#xD;
clinical trials of oral opioids for cancer pain.&#xD;
Results:&#xD;
The model developed in Paper I was tested and found to be sensitive. Thirty-seven&#xD;
randomised, controlled trials (RCTs) were included in paper II. The meta-analysis found that&#xD;
perioperative ketamine reduced 24 hr PCA morphine consumption and reduced PONV. In&#xD;
paper III, four RCT’s concerning ketamine as adjuvant to opioid for cancer pain were&#xD;
identified. Two were excluded due to flawed methodology. Both trials found that ketamine&#xD;
improved morphine analgesia. Meta-analysis was not appropriate. Thirty- four RCT’s were&#xD;
included in paper IV. Significant limitations in the trial methodology were identified.&#xD;
Conclusions:&#xD;
There is level 1 (strong) evidence that perioperative ketamine reduces 24 hr PCA morphine&#xD;
consumption, and post-operative nausea and vomiting. Adverse effects were mild or absent.There is currently insufficient evidence to permit conclusions regarding the benefits and&#xD;
harms of ketamine as adjuvant to opioid for cancer pain. Randomised, controlled trials are&#xD;
needed. Clinical pain trials require rigorous methodology if they are to produce reliable&#xD;
results. Recommendations for future analgesic trials in acute and cancer pain are made.</description>
  </item>
</rdf:RDF>

